BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33551068)

  • 21. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
    Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
    Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
    [No Abstract]   [Full Text] [Related]  

  • 22. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
    Hafliger E; Boccaccino A; Lapeyre-Prost A; Perret A; Gallois C; Antista M; Pilla L; Lecomte T; Scartozzi M; Soularue E; Salvatore L; Bourgeois V; Salati M; Tougeron D; Evesque L; Vaillant JN; El-Khoury R; Lonardi S; Cremolini C; Taieb J
    Eur J Cancer; 2022 Jun; 168():34-40. PubMed ID: 35436675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encorafenib, binimetinib and cetuximab combined therapy for patients with
    Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
    Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
    Al-Salama ZT
    Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective Analysis of Treatment Pathways in Patients With BRAF
    Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
    Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
    Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA
    Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
    Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with
    Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T
    ESMO Open; 2019; 4(6):e000590. PubMed ID: 31798981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
    Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
    Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF
    García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S
    Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Evolving Treatment Landscape in
    Tabernero J; Ros J; Élez E
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
    Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
    Future Oncol; 2024; 20(16):1047-1055. PubMed ID: 38357801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Encorafenib plus binimetinib in patients with
    Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
    Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of patients with BRAF
    Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
    ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
    Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
    J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of
    Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
    Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
    Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
    Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.